Clinical trial
Genistein, Gemcitabine, and Erlotinib in Treating Patients With Locally Advanced…
NCT00376948 · Barbara Ann Karmanos Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00376948 |
|---|---|
| Title | Genistein, Gemcitabine, and Erlotinib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer |
| Official title | Phase II Trial of Novasoy®, Gemcitabine, and Erlotinib in Locally Advanced or Metastatic Pancreatic Cancer |
| Lead sponsor | Barbara Ann Karmanos Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Dietary Supplement, Drug |
| Interventions | genistein, erlotinib hydrochloride, gemcitabine hydrochloride |
| Enrollment | 20 |
| Start date | May 1, 2005 |
| Primary completion | Mar 1, 2010 |
| Completion | Mar 1, 2010 |
| First posted | Sep 15, 2006 |
| Last update posted | Mar 1, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: